EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to ♀EFAX™ and reduction of menstrual discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006 by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of a health claim related to EFAX™ and reduction of menstrual
discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006
EFSA Publication; Tetens, Inge
Link to article, DOI:
10.2903/j.efsa.2013.3081
Publication date:
2013
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Publication (2013). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on
the substantiation of a health claim related to EFAX™ and reduction of menstrual discomfort pursuant to Article
13(5) of Regulation (EC) No 1924/2006. Parma, Italy: European Food Safety Authority.  (EFSA Journal; No. 2,
Vol. 11). DOI: 10.2903/j.efsa.2013.3081
  EFSA Journal 2013;11(2):3081 
 
Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the 
substantiation of a health claim related to ♀EFAX and reduction of menstrual discomfort pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006. EFSA Journal 2013;11(2):3081. [9 pp.]. doi:10.2903/j.efsa.2013.3081. Available online: 
www.efsa.europa.eu/efsajournal 
 
© European Food Safety Authority, 2013 
SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
♀EFAX™ and reduction of menstrual discomfort pursuant to Article 13(5) 
of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Nutrilinks Sarl submitted for authorisation of a health claim pursuant to Article 
13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Cyprus, the Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to ♀EFAX™ and reduction of menstrual discomfort. The food, ♀EFAX™, which is standardised pure 
krill oil and is the subject of the health claim, is sufficiently characterised. The claimed effect, reduction of 
menstrual discomfort, is a beneficial physiological effect. No human intervention studies from which conclusions 
could be drawn for the scientific substantiation of the claim were provided by the applicant. A cause and effect 
relationship has not been established between the consumption of ♀EFAX™ and reduction of menstrual 
discomfort. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Nutrilinks Sarl submitted for authorisation of a health claim pursuant 
to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Cyprus, the Panel 
on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to ♀EFAX™ and reduction of menstrual discomfort. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food that is the subject of the health claim is ♀EFAX™, which is standardised pure krill oil. The 
Panel considers that ♀EFAX™ is sufficiently characterised. 
The claimed effect is “contributes to reduce menstrual discomfort”. The target population proposed 
by the applicant is “women presenting with physiological and emotional symptoms associated with 
the menstruation cycle”. The Panel considers that reduction of menstrual discomfort is a beneficial 
physiological effect. 
The applicant performed a literature search and identified one published human intervention study as 
pertinent to the claim. This study was a double-blind, randomised, controlled parallel study in 
70 women who fulfilled the Diagnostic and Statistical Manual of Mental Disorders-III-Revised 
(DSM-III-R) criteria for premenstrual syndrome (PMS) and were randomised to consume daily 2 g of 
either krill oil (n=36) or fish oil (18 % EPA, 12 % DHA; n=34) for one month, and thereafter for eight 
days prior to and two days during menstruation for the two subsequent menstruation cycles. The krill 
oil administered in the study was manufactured in line with the applicant’s specifications. Severity of 
symptoms associated with PMS (breast tenderness, feeling overwhelmed, stress, irritability, 
depression, joint pain, weight gain, abdominal pain, swelling and bloating) was assessed at baseline 
and at days 45 and 90 using a self-assessment questionnaire and by the quantity of analgesic 
consumption for menstrual pain. None of the subjects dropped out of the study. Between group 
differences were analysed at day 90 using analysis of variance. 
The Panel notes that the information with respect to characterisation of the subjects recruited, and to 
the questionnaire used to assess changes in the severity of PMS symptoms, was insufficient to 
perform a full scientific evaluation; the Panel also notes the inadequate reporting and limitations of 
the statistical analysis. The Panel considers that no conclusions can be drawn from this study for the 
scientific substantiation of the claim. 
The Panel notes that no human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of ♀EFAX™ and reduction of menstrual discomfort. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 21/05/2012. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 On 12/06/2012 and on 18/07/2012, during the validation process of the application, EFSA 
sent a request to the applicant to provide missing information. 
 The applicant provided the missing information on 24/07/2012 (which had been made 
available to EFSA in electronic format on 13/07/2012) and on 30/07/2012 (which had been 
made available to EFSA in electronic format on 25/07/2012). 
 The scientific evaluation procedure started on 14/08/2012. 
 On 25/10/2012, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 30/10/2012 and restarted on 14/11/2012, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 22/11/2012, EFSA received the requested information (which had been made available to 
EFSA in electronic format on 15/11/2012).  
 During its meeting on 24/01/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to “♀EFAX™” 
and reduction of menstrual discomfort. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: ♀EFAX™ and reduction of 
menstrual discomfort. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of ♀EFAX™, a positive assessment of its safety, nor a decision on whether ♀EFAX™ is, 
or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Nutrilinks Sarl, Chemin de Beau-rivage 7, P.O. Box 96, 
CH-1000 Lausanne 21, Switzerland. 
Food/constituent as stated by the applicant 
According to the applicant, the food which is the subject of the claim is ♀EFAX™, a standardised 
pure krill oil extract. 
Health relationship as claimed by the applicant 
According to the applicant, the health relationship refers to the contribution to the maintenance of a 
normal menstruation cycle. Upon request from EFSA, the applicant clarified the health relationship to 
be related to the contribution to reduce menstrual discomfort. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wordings for the health claim: “♀EFAX™ contributes to 
maintain a normal menstruation cycle”, “♀EFAX™ helps to reduce the severity of symptoms related 
to the premenstrual syndrome and dysmenorrhoea”, “♀EFAX™ contributes to maintain a normal 
menstruation cycle by reducing the intensity of emotional symptoms, such as irritability and stress 
experienced before menstruation”, and “♀EFAX™ contributes to maintain a normal menstruation 
cycle by reducing the intensity of physical symptoms, such as abdominal discomfort and joint 
sensitivity experiences before and during menstruation”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is women presenting physiological and emotional 
symptoms associated with the menstruation cycle. The applicant proposed an intake of ♀EFAX™ of 
2,000 mg/day preferably in the morning for one month during the first cycle and thereafter a dose of 
2,000 mg/day for eight days prior to and two days during menstruation.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is ♀EFAX™, which is standardised pure krill oil. 
Krill oil is extracted from the crustacean Euphausia superba (Antarctic Krill). It has been authorised 
as a novel food ingredient
5
. The krill oil which is the subject of the claim complies with Commission 
Decision 2009/752/EC. The main constituents contained in the krill oil which is the subject of the 
claim are phospholipids (≥42.0 g/100 g), omega-3 fatty acids (≥26.5 g/100 g), comprising 
eicosapentaenoic acid (EPA, C20:5, ≥14.2 g/100 g) and docosahexaenoic acid (DHA, C22:6, 
≥8.5 g/100 g), and saturated fatty acids (25.0±5 g/100 g). The content of esterified astaxanthin 
amounts to around 1,000 to 1,500 mg/kg. Phospholipids, fatty acids and astaxanthin can be measured 
in foods by established methods. Information on the stability and the batch-to-batch variability of the 
product has been provided. 
                                                     
5  2009/752/EC: Commission Decision of 12 October 2009 authorising the placing on the market of a lipid extract from 
Antarctic Krill Euphausia superba as a novel food ingredient under Regulation (EC) No 258/97 of the European 
Parliament and of the Council (notified under document C(2009) 7647), OJ L 268, 13.10.2009, p. 33–34. 
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The Panel considers that the food, ♀EFAX™, which is the subject of the health claim, is sufficiently 
characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect is “contributes to reduce menstrual discomfort”. The target population proposed 
by the applicant is “women presenting with physiological and emotional symptoms associated with 
the menstruation cycle”. 
Menstrual discomfort can be assessed as changes in the severity of symptoms related to the 
premenstrual syndrome and/or dysmenorrhoea using validated questionnaires. 
The Panel considers that reduction of menstrual discomfort is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, ScienceDirect, Blackwell Synergy, Wiley 
InterScience, Mary Ann Liebert, Scirus, IBIDS, SciFinder Scholar, Pascal, Google and SCOPUS with 
the search terms [“Neptune krill oil”] AND [“premenstrual syndrome” OR “dysmenorrhoea”]. No 
time limits were applied to the search. Hand searches in specialised libraries and web research were 
also performed. The Panel notes the limitations of the literature search performed by the applicant. 
The applicant identified one published human intervention study (Sampalis et al., 2003) as pertinent 
to the claim. 
In the double-blind, randomised, controlled parallel study by Sampalis et al. (2003), 70 women (mean 
age approx. 33 years) who fulfilled the Diagnostic and Statistical Manual of Mental Disorders-III-
Revised (DSM-III-R) criteria for premenstrual syndrome (PMS) were randomised to consume daily 
2 g of either krill oil (n=36) or fish oil (18 % EPA, 12 % DHA; n=34) for one month and thereafter 
for eight days prior to and two days during menstruation for the two subsequent menstruation cycles. 
The applicant was invited to clarify whether subjects included in the study were diagnosed with late 
luteal phase dystrophic disorder (LPDD) to which the diagnostic criteria of the DSM-III-R relate. The 
applicant replied that according to the American College of Obstetricians and Gynecologists, the 
DSM set of criteria for diagnosing premenstrual dysphoric disorder (PMDD, or LPDD in DSM-III-R) 
is similar to the diagnostic criteria used for PMS, and that only subjects having less severe forms of 
PMS (not leading to functional impairment) were recruited for the study. The Panel considers that the 
characterisation of the study population with respect to the diagnosis of LPDD, a disorder typified in 
DSM-III-R, is unclear. 
The krill oil administered in the study was manufactured in line with the applicant’s specifications. 
Subjects had to discontinue use of any food supplements two weeks prior to study initiation, but were 
allowed to continue use of analgesics and oral contraceptives throughout the study. The Panel notes 
that no information was provided about the use of oral contraceptives by the study subjects prior to or 
during the study. Severity of symptoms associated with PMS (breast tenderness, feeling 
overwhelmed, stress, irritability, depression, joint pain, weight gain, abdominal pain, swelling and 
bloating) was assessed at baseline and at days 45 and 90 using a self-assessment questionnaire in 
which symptom severity was rated on a 11-point Likert scale, and by the quantity of analgesic 
consumption for menstrual pain. The applicant was asked to clarify the origin of the questionnaire 
used in the study and to provide a copy of it, as well as information on its validation to assess changes 
in the severity of PMS symptoms. The applicant did not provide a copy of the questionnaire as 
requested, nor evidence for the validation of the questionnaire as used in the study to assess changes 
in the severity of PMS symptoms. The Panel notes that the validity of the questionnaire as used in the 
study to assess changes in the severity of PMS symptoms during an intervention is unclear. The Panel 
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also notes that the quantity of ad libitum analgesic consumption is not a direct measure of changes in 
the severity of PMS symptoms. 
None of the subjects dropped out of the study. Between group differences were analysed at day 90 
using analysis of variance (ANOVA). The applicant was invited to comment on why baseline values, 
medication use (analgesics and contraceptives) and repeated measures were not taken into account in 
the analysis. The applicant replied that baseline values and medication use were not considered in 
data analyses because they “appeared” to be “well-balanced” between the two treatment groups, and 
that between-group comparisons for PMS symptoms were only made at 90 days in order to limit 
multiple comparisons. The Panel notes the inadequate reporting and limitations of the statistical 
analysis performed (e.g. biological variability over time and differences in medication use between 
groups were not considered).  
The Panel notes that the information with respect to characterisation of the subjects recruited and to 
the questionnaire used to assess changes in the severity of PMS symptoms is insufficient to perform a 
full scientific evaluation; the Panel also notes the inadequate reporting and limitations of the 
statistical analysis. The Panel considers that no conclusions can be drawn from this study for the 
scientific substantiation of the claim. 
The Panel notes that no human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of ♀EFAX™ and reduction of menstrual discomfort. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, ♀EFAX™, which is standardised pure krill oil and is the subject of the claim, is 
sufficiently characterised. 
 The claimed effect is “contributes to reduce menstrual discomfort”. The target population 
proposed by the applicant is “women presenting with physiological and emotional symptoms 
associated with the menstruation cycle”. Reduction of menstrual discomfort is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
♀EFAX™ and reduction of menstrual discomfort. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on ♀EFAX™ and reduction of menstrual discomfort pursuant to Article 
13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0354_CY). July 2012. Submitted by 
Nutrilinks Sarl. 
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GLOSSARY AND ABBREVIATIONS 
ANOVA Analysis of variance 
DHA Docosahexaenoic acid 
DSM-III-R Diagnostic and Statistical Manual of Mental Disorders-III-Revised 
EPA Eicosapentaenoic acid 
LPDD Luteal phase dystrophic disorder 
PMDD Premenstrual dysphoric disorder  
PMS Premenstrual syndrome 
